Tokyo Tape
Sign in
← Nihon Chouzai

Quarterly report · Q1

3341.TEDINET S100RN0R
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥81.8bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥313.3bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥74.7bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥1.6bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥892m2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥1.6bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥7.7bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥913m2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥1.6bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥925m2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥659m2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.5bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥391m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥659m2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥391m2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥199.2bnat 2023-06-30Cons.Assets
Total assets¥185.3bnat 2023-03-31Cons.Assets
Total assets¥195.3bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥142.4bnat 2023-06-30Cons.Liabilities
Total liabilities¥128.8bnat 2023-03-31Cons.Liabilities
Net assets / equity¥56.8bnat 2023-06-30Cons.Net assets
Net assets / equity¥56.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥52.9bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥31.2bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥23.8bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥22.062023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥148.922022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥13.052022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio28.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio30.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio27.1%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥3.6bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥3.6bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥1.9bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥72.3bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥72.3bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥2.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥2.6bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥2.6bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥5m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥484m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥10.5bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥7.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥3.6bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥126m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥85.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥81.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥3.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥3.5bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥1.8bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥355m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥10.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥6.3bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥270m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥78.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥74.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥2.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 351
ItemContextValueUnit
AssetsPrior1YearInstant185297000000JPY
AssetsCurrentQuarterInstant199201000000JPY
Accounts payable tradePrior1YearInstant47916000000JPY
Accounts payable tradeCurrentQuarterInstant60512000000JPY
Electronically recorded obligations operating clPrior1YearInstant1476000000JPY
Electronically recorded obligations operating clCurrentQuarterInstant1845000000JPY
Short term loans payablePrior1YearInstant2000000000JPY
Short term loans payableCurrentQuarterInstant900000000JPY
Current portion of long term loans payablePrior1YearInstant10390000000JPY
Current portion of long term loans payableCurrentQuarterInstant10645000000JPY
Income taxes payablePrior1YearInstant2640000000JPY
Income taxes payableCurrentQuarterInstant1407000000JPY
Provision for bonusesPrior1YearInstant3892000000JPY
Provision for bonusesCurrentQuarterInstant2138000000JPY
Provision for directors bonusesPrior1YearInstant68000000JPY
Provision for directors bonusesCurrentQuarterInstant－JPY
Other clPrior1YearInstant8665000000JPY
Other clCurrentQuarterInstant11337000000JPY
Current liabilitiesPrior1YearInstant77050000000JPY
Current liabilitiesCurrentQuarterInstant88787000000JPY
Long term loans payablePrior1YearInstant44640000000JPY
Long term loans payableCurrentQuarterInstant46424000000JPY
Provision for directors retirement benefitsPrior1YearInstant79000000JPY
Provision for directors retirement benefitsCurrentQuarterInstant82000000JPY
Net defined benefit liabilityPrior1YearInstant2464000000JPY
Net defined benefit liabilityCurrentQuarterInstant2522000000JPY
Other nclPrior1YearInstant4579000000JPY
Other nclCurrentQuarterInstant4612000000JPY
Noncurrent liabilitiesPrior1YearInstant51763000000JPY
Noncurrent liabilitiesCurrentQuarterInstant53641000000JPY
LiabilitiesPrior1YearInstant128814000000JPY
LiabilitiesCurrentQuarterInstant142429000000JPY
Capital stockPrior1YearInstant3953000000JPY
Capital stockCurrentQuarterInstant3953000000JPY
Capital surplusPrior1YearInstant10926000000JPY
Capital surplusCurrentQuarterInstant10926000000JPY
Retained earningsPrior1YearInstant45216000000JPY
Retained earningsCurrentQuarterInstant45501000000JPY
Treasury stockPrior1YearInstant-3600000000JPY
Treasury stockCurrentQuarterInstant-3599000000JPY
Shareholders equityPrior1YearInstant56495000000JPY
Shareholders equityCurrentQuarterInstant56782000000JPY
Remeasurements of defined benefit plansPrior1YearInstant-12000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant-10000000JPY
Valuation and translation adjustmentsPrior1YearInstant-12000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant-10000000JPY
Net assetsPrior1YearInstant56483000000JPY
Net assetsCurrentQuarterInstant56771000000JPY
Liabilities and net assetsPrior1YearInstant185297000000JPY
Liabilities and net assetsCurrentQuarterInstant199201000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass